A fresh probe into the excessive prices of pharmaceutical drugs
has been launched.
A week-long investigation on the production costs of 28 kinds of
drugs, including 21 Western ones and seven traditional Chinese
medicines, took place before the May Day holiday.
The National Development and Reform Commission ordered the
companies that produced them to fill out a detailed questionnaire
on the production process in a bid to calculate the true costs
involved.
Officers then decided whether the pharmaceutical factories
needed to be visited in person as well.
The results of the investigation are still unknown.
The probe aims to help the commission gain a better
understanding of the cost of drug production, and to provide sound
support for it to limit the sale price of drugs in the future, an
unidentified official was quoted by Beijing Times as
saying.
In recent years, many patients have been wary of seeking medical
treatment because of the soaring prices of various drugs.
The commission will use the results of its probe to launch the
18th national campaign to reduce the sale price of drugs in the
country, which will cover 130 kinds of Western drugs and at least
30 traditional Chinese medicines, sources said.
Unlike previous campaigns, anti-virus and anti-cancer drugs will
be included. It will be the first time some producers of
traditional Chinese medicines will be asked to cut their
prices.
The prices of more than 1,500 types of medicines and drugs have
been reduced by around 20-40 percent in previous campaigns.
However, many people feel medical services and treatments are
still too expensive.
It has been easy for Chinese factories in previous years to
simply re-brand drugs that are ordered to become cheaper, so that
they can continue to be sold at a high price but under a different
name.
Commercial bribery also widely exists between distributing
agents of pharmaceutical companies and hospitals, which sell the
majority of drugs in the country.
Many doctors are given bribes to sell expensive drugs in favour
of cheaper ones to patients when they write prescriptions.
Experts have also called on authorities to regulate the
marketing process of drugs, during which the sale price of a drug
to patients is usually 10 times more than that of its production
cost.
Last month, the State Food and Drug Administration opened a
centre to improve the practice of registering new drugs, making it
impossible for factories to stop the production of a drug and
merely register a new name for it.
The Ministry of Health has also told all hospitals to strengthen
their management of doctors to prevent commercial bribery between
doctors and drug distribution agents.
(China Daily May 9, 2006)